1. Li, Gang, Yan, Ke, Zhang, Wanyi, Pan, Haiyan, Guo, Pengxiang. 2024. ARDS and aging: TYMS emerges as a promising biomarker and therapeutic target. In Frontiers in immunology, 15, 1365206. doi:10.3389/fimmu.2024.1365206. https://pubmed.ncbi.nlm.nih.gov/38558817/
2. Wang, Liang, Shi, Caiyan, Yu, Jie, Xu, Yilin. 2022. FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma. In Cancer cell international, 22, 47. doi:10.1186/s12935-021-02372-2. https://pubmed.ncbi.nlm.nih.gov/35093082/
3. Zhang, Fen, Ye, Jiecheng, Guo, Wenjing, Wang, Liyuan, Han, Anjia. 2022. TYMS-TM4SF4 axis promotes the progression of colorectal cancer by EMT and upregulating stem cell marker. In American journal of cancer research, 12, 1009-1026. doi:. https://pubmed.ncbi.nlm.nih.gov/35411242/
4. Saif, Muhammad W. . Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics. In Anti-cancer drugs, 30, 431-434. doi:10.1097/CAD.0000000000000737. https://pubmed.ncbi.nlm.nih.gov/30875351/
5. Lima, Aurea, Azevedo, Rita, Sousa, Hugo, Seabra, Vítor, Medeiros, Rui. . Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics. In Pharmacogenomics, 14, 1337-51. doi:10.2217/pgs.13.118. https://pubmed.ncbi.nlm.nih.gov/23930679/
智鼠故事 
